|Chemical and physical data|
|Molar mass||358.17 g/mol|
|3D model (Jmol)||Interactive image|
SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
The code number SDB-005 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).
However SDB-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in Europe as a designer drug, and was entered into the EMCDDA synthetic drug database under this name. Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.
- "SDB-005". Cayman Chemical. Retrieved 27 June 2015.
- "The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse". ABS Chemical Neuroscience. 4 (7): 1081–1092. July 2013. doi:10.1021/cn400035r. PMC 3715837. PMID 23551277.
- EWS_EU: Neue Psychoaktive Substanzen, April 2015